Axogen, a Tampa-based regenerative medicine company dedicated to creating nerve repair solutions, has had an eventful August.
Axogen’s board of directors announced Aug. 8 that a new CEO would foster their increased focus on commercial expansion and profitability. An earnings call that day highlighted a 25.6% year-over-year increase in second-quarter revenue to $47.9 million, gross margins decreasing by 73.8% and a new nerve product.
|